{"id":"W4292103594","doi":"10.1136/jitc-2022-004761","title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Hôtel-Dieu de Québec","funders":"Foundation Medicine; National Center for Advancing Translational Sciences; Ono Pharmaceutical; Clovis Oncology; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Nivolumab; Internal medicine; Oncology; Cohort; Progression-free survival; Cancer; Urology; Chemotherapy; Androgen receptor; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00103556,0.000225723,0.0005774921,0.0001043564,0.0009046557,0.00008242083,0.0002769083,0.00003738382,0.0005810683],"category_scores_gemma":[0.00007381844,0.0001442565,0.0004389505,0.0002287776,0.0001280725,0.0001297954,0.00002678936,0.0003829201,5.086603e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009724737,"about_ca_system_score_gemma":0.002459996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002132175,"about_ca_topic_score_gemma":0.0002993369,"domain_scores_codex":[0.9975715,0.0001226769,0.000882607,0.0002792218,0.0006934016,0.0004505693],"domain_scores_gemma":[0.9980254,0.0004154944,0.0007217198,0.0003131067,0.0004186554,0.0001056871],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.815492,0.0006151149,0.00003844797,0.00008607606,0.002498703,0.00001996059,0.005383395,0.0006558246,0.0816623,0.00004386511,0.02018117,0.07332315],"study_design_scores_gemma":[0.5875027,0.01059025,0.0002117026,0.0002371539,0.0007293828,0.00003007846,0.00254562,0.001321325,0.02669192,0.0013131,0.3685461,0.0002807626],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9094368,0.05319183,0.0002501772,0.01613677,0.002551972,0.006461146,0.01188878,0.00002491013,0.00005759178],"genre_scores_gemma":[0.9357943,0.02761353,0.002246888,0.00132044,0.002353568,0.01010761,0.0009479005,0.0002017668,0.01941401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3483649,"threshold_uncertainty_score":0.6957971,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07347743674206077,"score_gpt":0.4234544933584976,"score_spread":0.3499770566164369,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}